Endometrial Cancer: Updated FIGO Staging 2023 PDF
Document Details
Uploaded by RichGardenia4079
Helwan University
2023
Karim A. Al Esh
Tags
Summary
This presentation details the updated 2023 FIGO staging for endometrial cancer. It covers various aspects including histology, molecular profiling, staging, and management.
Full Transcript
Endometrial cancer: Updated FIGO staging 2023 KARIM A. AL ESH, MD Consultant and Lecturer OF OBGYN FACULTY OF MEDECINE HELWAN UNIVERSITY [email protected] 1 Contents Declaration Histological types Molecular profiling St...
Endometrial cancer: Updated FIGO staging 2023 KARIM A. AL ESH, MD Consultant and Lecturer OF OBGYN FACULTY OF MEDECINE HELWAN UNIVERSITY [email protected] 1 Contents Declaration Histological types Molecular profiling Staging 2 Declaration I declare I have no conflict of interest 8/7/23 3 Histological types Non aggressive and aggressive 8/7/23 4 Histological types: 5th edition of WHO classification Class 1 Class 2 Class 3 Class 4 Class 5 Class 6 Class 7 Class 8 Unusual types (Mesonephric- Low-grade endometrioid GIT mucinous type (G1, G2) Undifferentiated Carcinosarcoma like) Serous Clear cell Mixed High-grade endometrioid (G3) 8/7/23 5 Histology in this revised 2023 FIGO update Non-aggressive Low-grade endometroid (G1, G2) Aggressive High-grade endometroid (G3) Serous Clear cell Mixed Undifferentiated Carcinosarcoma Unusual Gastro-intestinal mucinous type 8/7/23 6 Histological grades: according to the % of the solid non-glandular component Grade 01 Grade 02 Grade 03 50% 8/7/23 7 Grade 3 Endometroid Prognostically, clinically, and molecularly heterogeneous disease They will benefit the most from applying molecular profiling 8/7/23 8 Molecular profiling 9 Molecular classification POLEmut Excellent prognosis Respond to immunotherapy P53abn Poor prognosis Mismatch repair defect (MMRd) Intermediate prognosis Non-specific molecular profile (NSMP) Intermediate prognosis 8/7/23 10 Staging with molecular notation Stage IAmPOLEmut Stage IICmP53abn m is for molecular classification 8/7/23 11 FIGO recommendation Molecular profiling is recommended for all cases Of greater importance in Stage I and Stage II, especially Grade 3 For prognostic risk-group stratification For the potential use of adjuvant therapy For the potential use of immune checkpoint inhibitors (ICI) 8/7/23 12 8/7/23 13 Lymph-vascular space invasion: WHO 2021 No LVSI Focal:
